CalciMedica (CALC) Expected to Announce Earnings on Thursday

CalciMedica (NASDAQ:CALC) will likely be releasing its results before the market opens on Thursday, March 26th. Analysts expect CalciMedica to post earnings of ($0.55) per share for the quarter.

CalciMedica (NASDAQ:CALC) last released its earnings results on Tuesday, March 3rd. The company reported ($0.69) earnings per share for the quarter. On average, analysts expect CalciMedica to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CalciMedica Trading Down 1.3%

Shares of NASDAQ CALC opened at $0.82 on Thursday. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 1.39. The business has a fifty day simple moving average of $2.00 and a two-hundred day simple moving average of $3.22. The firm has a market cap of $12.94 million, a PE ratio of -0.42 and a beta of 0.60. CalciMedica has a twelve month low of $0.46 and a twelve month high of $7.20.

Institutional Trading of CalciMedica

A number of hedge funds have recently modified their holdings of the stock. Cetera Investment Advisers raised its position in CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares in the last quarter. Jane Street Group LLC purchased a new stake in CalciMedica in the 4th quarter worth approximately $127,000. Envestnet Asset Management Inc. boosted its position in CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after purchasing an additional 34,386 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of CalciMedica during the 4th quarter worth approximately $506,000. Finally, Renaissance Technologies LLC grew its stake in shares of CalciMedica by 26.1% during the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock worth $582,000 after purchasing an additional 18,300 shares during the period.

Analyst Upgrades and Downgrades

CALC has been the subject of several recent research reports. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research report on Thursday, January 29th. Oppenheimer decreased their price target on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a report on Thursday, March 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of CalciMedica in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded CalciMedica to a “sell” rating in a research note on Saturday, January 17th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $13.00.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.